Patents Assigned to Applied Research Systems ARS Holding N.V.
  • Intracellular modulators of apoptopic cell death pathways
    Publication number: 20050095681
    Abstract: A DNA sequence encoding a glucocorticoid-induced leucine-zipper family related protein (GILR), isoforms, fragments or analogs thereof, said GILR, isoforms, fragments or analogs thereof capable of inhibiting apoptosis and stimulating lymphocyte activity, GILR proteins, isoforms, analogs, fragments and derivatives thereof encoded by the aforesaid DNA sequence, their preparation and uses.
    Type: Application
    Filed: December 16, 2004
    Publication date: May 5, 2005
    Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
    Inventor: Carlo Riccardi
  • Gonadotrophins for folliculogenesis
    Publication number: 20050085412
    Abstract: The invention provides an FSH preparation having a high degree of sialylation, and showing increased efficacy.
    Type: Application
    Filed: October 15, 2002
    Publication date: April 21, 2005
    Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
    Inventors: Ernest Loumaye, Carlo Giartosio
  • METHODS OF INCERASING PROTEIN EXPESSION LEVELS
    Publication number: 20050074840
    Abstract: Abstract of the Disclosure The present invention relates to methods of increasing protein expression levels whereby at least one amino acid in a protein amino acid sequence is substituted for the amino acid, proline. Preferably, the substitution occurs within 15 amino acids, more preferably within 10 amino acids and most preferably within 5 amino acids of a cysteine amino acid residue. The present invention not only includes methods for polypeptides with proline substitutions, but also polynucleotides with codon substitutions for which a codon for any amino acid, except proline, is substituted for a codon encoding for proline.
    Type: Application
    Filed: September 13, 2004
    Publication date: April 7, 2005
    Applicant: Applied Research Systems ARS Holding N.V.
    Inventors: William Brondyk, Xuliang Jiang, Rene Schweickhardt
  • Site-specific preparation of polyethlene glycol-GRF conjugates
    Patent number: 6869932
    Abstract: A method is described for the site-specific preparation of hGRF-PEG conjugates containing one or more PEG units (per mole of hGRF) covalently bound to Lys12 and/or Lys21 and/or N?, characterized in that the conjugation reaction between the hGRF peptide and activated PEG is carried out in solution and the desired hGRF-PEG conjugate can be purified by chromatography. The conjugates prepared by this method, as well as their use in the treatment, prevention or diagnosis of growth hormone deficiency, are also an object of the present invention.
    Type: Grant
    Filed: November 20, 2002
    Date of Patent: March 22, 2005
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventors: Francesco Maria Veronese, Paolo Caliceti, Oddone Schiavon
  • Combined treatment of multiple sclerosis
    Patent number: 6869600
    Abstract: The use of growth hormone (GH) together with an interferon (IFN) to produce a pharmaceutical composition for treating multiple sclerosis and/or other demyelinating diseases is disclosed. Disclosed are also pharmaceutical compositions for treating multiple sclerosis and/or other demyelinating diseases. Disclosed are also pharmaceutical compositions for the simultaneous, separate or sequential use of its active ingredients for the above specified therapy. In particular, the advantage of EP0003504 of GH together with IFN-? to produce a pharmaceutical composition for the treatment of multiple sclerosis are shown.
    Type: Grant
    Filed: March 20, 2000
    Date of Patent: March 22, 2005
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventors: Rémy Sadoul, Sonia Pagliusi
  • Pharmaceutically active compounds and methods of use
    Publication number: 20050054706
    Abstract: The invention provides substituted pyrazolidinone compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing various cancers, inflammation, septic shock, preterm labor, infertility, pain, and ischemia, and other diseases and disorders associated with MEK-1 and/or ERK-2 activation.
    Type: Application
    Filed: October 23, 2002
    Publication date: March 10, 2005
    Applicant: Applied Research Systems ARS Holding N.V.
    Inventors: Stephen Arkinstall, Antonio Arulanandam, Xuliang Jiang, Sharad Magar, Roustem Nabioullin, John Zhang, Peter Blume-Jensen
  • Use of lh in controlled ovarian hyperstimulation
    Publication number: 20050049199
    Abstract: The invention provides a new use for LH, and analogues having LH-activity for aiding folliculogenesis in controlled ovarian hyperstimulation (COH), in which the LH or an analogue thereof is administered during a priming period lasting from day 1 to about day 4 of the stimulatory phase in COH.
    Type: Application
    Filed: September 12, 2002
    Publication date: March 3, 2005
    Applicant: Applied Research Systems ARS Holding N. V.
    Inventors: Stephen Hillier, Colin Howles
  • Compound B as angiogenic agent in combination with human growth factors
    Patent number: 6855684
    Abstract: The present invention refers to the use of Compound B as angiogenic agent in combination with human growth factors.
    Type: Grant
    Filed: January 9, 2001
    Date of Patent: February 15, 2005
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventors: Marina Ziche, Silvia Donini, Francesco Borrelli
  • IFN-? liquid formulations
    Patent number: 6852314
    Abstract: Interferon-? liquid formulations stabilized with a polyol, a non-reducing sugar or an amino acid. In particular, the formulations are stabilized with a polyol, such as mannitol. The formulations, preferably, furthermore comprise a buffer, such as acetate buffer, at a pH comprised between 3.0 and 4.0 and human albumin at a minimum quantity. The interferon-? is preferably recombinant.
    Type: Grant
    Filed: May 15, 1995
    Date of Patent: February 8, 2005
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventors: Fabrizio Samaritani, Patrizia Natale
  • Monoclonal antibodies to the human LDL receptor, their production and use
    Patent number: 6849720
    Abstract: There are provided monoclonal antibodies to the LDL receptor which are useful for the identification and purification of LDL and in treatment of e.g. hepatitis C infection.
    Type: Grant
    Filed: March 8, 2001
    Date of Patent: February 1, 2005
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventors: Nachum Yonah, Dany Suissa, Ilana Belzer, Francesco Antonetti, Moshe Smolarsky, Michel Dreano
  • IL-6 antagonist peptides
    Patent number: 6838433
    Abstract: The present invention relates to IL-6 antagonist peptides, isolatable from a peptide library through the two-hybrids system by their ability to bind to the intracellular domain of gp130 and containing at least 5 amino acids. In particular, such peptides comprise the amino acid sequence SEQ ID NO: 6, as well as salts, functional derivatives, precursors and analogs thereof. The present invention also provides the peptides in substantially purified form, in order to be suitable for use in pharmaceutical compositions as active ingredient in pathologies that require IL-6 activity inhibition.
    Type: Grant
    Filed: February 4, 2003
    Date of Patent: January 4, 2005
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventors: Ottaviano Serlupi-Crescenzi, Alessandro Bressan, Linda Della Pietra, Anna Rita Pezzotti
  • IFN-beta liquid formulations
    Publication number: 20040265270
    Abstract: Interferon-beta liquid formulations stabilized with a polyol, a non-reducing sugar or a amino acid. In particular, the formulations are stabilized with a polyol, such as mannitol. The formulations, preferably, furthermore comprise a buffer, such as acetate buffer, at a pH comprised between 3.0 and 4.0 and human albumin at a minimum quantity. The interferon-beta is preferably recombinant.
    Type: Application
    Filed: July 16, 2004
    Publication date: December 30, 2004
    Applicant: Applied Research Systems ARS Holding N.V.
    Inventors: Fabrizio Samaritani, Patrizia Natale
  • Intracellular glucocorticoid-induced leucine zippers modulators of apoptic cell death pathways
    Patent number: 6833348
    Abstract: A DNA sequence encoding a glucocorticoid-induced leucine-zipper family related protein (GILR), isoforms, fragments or analogs thereof said GILR, isoforms, fragments or analogs thereof capable of inhibiting apoptosis and stimulating lymphocyte activity, GILR proteins, isoforms, analogs, fragments and derivatives thereof encoded by the aforesaid DNA sequence, their preparation and uses.
    Type: Grant
    Filed: February 11, 2000
    Date of Patent: December 21, 2004
    Assignee: Applied Research Systems Ars Holding N.V.
    Inventor: Carlo Riccardi
  • Hybrid heterodimeric protein hormone and method of using same
    Publication number: 20040230034
    Abstract: A hybrid protein includes two coexpressed amino acid sequences forming a dimer. Each sequence contains the binding portion of a receptor, such as TBP1 or TBP2, or a ligand, such as IL-6, IFN-&bgr; and TPO, linked to &agr; subunit of a natural heterodimeric scaffold. Each coexpressed sequence contains a corresponding subunit so as to form a heterodimer upon expression. Corresponding DNA molecules, expression vectors and host cells are also disclosed as are pharmaceutical compositions and a method of producing such proteins.
    Type: Application
    Filed: December 1, 2003
    Publication date: November 18, 2004
    Applicant: Applied Research Systems ARS Holding N.V.
    Inventors: Robert K. Campbell, Bradford A. Jameson, Scott C. Chappel
  • Gonadotrophins
    Publication number: 20040224895
    Abstract: The present invention relates to the use of gonadotrophins in the induction of folliculogenesis in anovulatory women. In particular, it relates to the use of LH (or an equivalent dosage of hCG) in the production of a medicament for inducing folliculogenesis in anovulatory women at a specified daily doses. In certain embodiments, LH may be used in conjunction with FSH.
    Type: Application
    Filed: June 14, 2004
    Publication date: November 11, 2004
    Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
    Inventors: Stephen Franks, Stephen Hillier
  • Intracellular modulators of apoptopic cell death pathways
    Publication number: 20040194160
    Abstract: A DNA sequence encoding a glucocorticoid-induced leucine-zipper family related protein (GILR), isoforms, fragments or analogs thereof, said GILR, isoforms, fragments or analogs thereof capable of inhibiting apoptosis and stimulating lymphocyte activity, GILR proteins, isoforms, analogs, fragments and derivatives thereof encoded by the aforesaid DNA sequence, their preparation and uses.
    Type: Application
    Filed: July 31, 2003
    Publication date: September 30, 2004
    Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
    Inventor: Carlo Riccardi
  • Amine derivatives for the treatment of apoptosis
    Patent number: 6770656
    Abstract: The present invention is related to substituted amine derivatives notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such amine derivatives of formula (I). Said substituted amine derivatives are efficient modulators, in particular inhibitors, of the Bax function and/or activation. The present invention is furthermore related to novel substituted amine derivatives as well as methods of their preparation.
    Type: Grant
    Filed: December 26, 2002
    Date of Patent: August 3, 2004
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventors: Serge Halazy, Matthias Schwarz, Bruno Antonsson, Agnes Bombrun, Jean-Claude Martinou, Dennis Church
  • Process for the synthesis of (1-H)-benzo[c]quinolizin-3-ones derivatives
    Patent number: 6723850
    Abstract: The present invention refers to a process for the preparation of (1H)-benzo[c]quinolizin-3-ones derivatives of general formula (I) which involves only three steps and the use, as starting products, of commercially available, or easily preparable, compounds. The compounds of formula (I) are useful as inhibitors of 5&agr;-reductases.
    Type: Grant
    Filed: May 25, 2001
    Date of Patent: April 20, 2004
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventors: Antonio Guarna, Mario Serio, Ernesto Occhiato
  • Novel glycoproteins and methods of use thereof
    Publication number: 20040072214
    Abstract: The present invention provides novel isolated ARP/BRP polynucleotides and the membrane-associated or secreted polypeptides encoded by the ARP/BRP polynucleotides. Also provided are ARP and BRP protein multimers. Further provided are the antibodies that immunospecifically bind to a ARP/BRP polypeptide or any derivative, variant, mutant or fragment of the ARP/BRP polypeptide, a ARP/BRP multimer polynucleotide or antibody. The invention additionally provides methods in which the ARP/BRP polypeptide, multimer, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, e.g. reproductive disorder, as well as to other uses.
    Type: Application
    Filed: June 5, 2003
    Publication date: April 15, 2004
    Applicant: Applied Research Systems ARS Holding N.V.
    Inventors: Nabil El Taylor, Susan Kiernan, Robert K. Campbell, Christie A. Kelton, Chaomei He
  • Tumor necrosis factor antagonists and their use in endometriosis
    Publication number: 20040057954
    Abstract: Tumor necrosis factor antagonists are administered in therapeutically effective doses to treat and/or prevent endometriosis. The antagonists of this invention typically are selected among various classes of molecules but preferably are soluble TNF receptors. The antagonists are useful for the regression of endometriotic lesions and, if combined with other active ingredients, for amelioration of related disorders, like infertility.
    Type: Application
    Filed: September 22, 2003
    Publication date: March 25, 2004
    Applicant: Applied Research Systems ARS Holding N.V.
    Inventors: Francesco Borrelli, Mauro D'Antonio, Fabrizio Martelli